McCormick & Company, Incorporated (MKC) Stock Price Today
Aura AI Summary
Key Stats
- $14.58BMarket Cap
- -Volume
- Consumer StaplesSector
- $71.6552W High
- $45.6052W Low
- -Typical Hold Time
- $19.18BEnterprise Value
- 3.54%Div Yield
- -Trading Activity
Track McCormick & Company, Incorporated (MKC) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, McCormick & Company, Incorporated has traded between a low of $45.6 and a high of $71.65, highlighting its annual price range. Buy and sell McCormick & Company, Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Most Recent News
Alumis stock plunges 57% after lupus drug trial fails, but psoriasis drug progress continues.
Alumis' stock dropped 56.58% after its Phase II lupus drug trial failed to meet main goals, causing a significant market reaction. However, positive results in a subgroup of lupus patients with a high interferon gene signature offer a potential path ...
SPACs, biotech, geothermal, and AI stocks rally with major deals and volatility driving gains
SPAC stocks like Rising Dragon Acquisition surged nearly 47% amid volatility, while biotech firm bioAffinity Technologies jumped 44% after a reverse stock split. Renewable energy company Fervo Energy gained 28% following a major geothermal power deal...
Alumis plunges 57% after trial failure; Enovis falls 16% on robotics acquisition news
Alumis Inc. shares dropped 56.76% after its Phase 2b trial for a lupus drug failed to meet key goals, though some patient groups showed promise. Enovis Corporation shares fell 16.51% following its announcement to acquire eCential Robotics for €155 mi...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.